Allergan: Paul Bisaro
Allergan has rung the changes at the company by announcing that another member of its board of directors would be stepping down. The company has stated that the action was taken as “part of the company’s ongoing board refreshment process”.
The member of the board in question is Paul Bisaro, who has held a position at the company for over a decade. For a time, Bisaro held the position of executive chairman before pursuing other ventures alongside his board positon. He is currently the CEO of Impax, a generics company that recently merged with Amneal Pharmaceuticals.
“Paul Bisaro is a transformational leader who created the building blocks necessary to bring this company from a mid-sized US generics company to a global branded pharmaceutical leader. I deeply appreciate Paul's business insight and will miss having him as a board colleague,” said Brent Saunders, Allergan's chairman and CEO.
Allergan noted that due to Bisaro stepping away from the board, there are now 11 members on the board and 10 of these are independent from the company. In addition, it noted that the average length of time each existing member has sat on the board is less than five years.